Skip to Content

Inflammatory Joint Disease: Adalimumab Serum Levels, Anti-Drug Antibodies and Drug Survival

In this MEDtalk, Ingrid Jyssum presents a research project related to the use of therapeutic drug monitoring in the treatment of inflammatory joint diseases. The study focuses on the drug adalimumab and its serum levels and drug survival as well as the impact of anti-drug antibodies on treatment outcomes.

Ingrid Jyssum

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top